Solacium Pharma S.R.L. Sustainability Profile
Solacium Pharma S.R.L., a prominent player in the pharmaceutical industry, is headquartered in Romania (RO) and operates extensively across various regions. Founded in 2015, the company has quickly established itself as a leader in the development and distribution of innovative healthcare solutions. Specialising in high-quality generic medications and advanced therapeutic products, Solacium Pharma is committed to enhancing patient care through its unique formulations and rigorous quality standards. The company’s dedication to research and development has led to significant milestones, positioning it as a trusted name in the market. With a focus on affordability and accessibility, Solacium Pharma continues to make strides in the pharmaceutical landscape, ensuring that essential medications are available to those in need.
DitchCarbon Score
How does Solacium Pharma S.R.L.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solacium Pharma S.R.L.'s score of 11 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solacium Pharma S.R.L., headquartered in Romania, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Zentiva Group, a.s., which may influence its climate commitments and performance metrics. While Solacium Pharma has not established its own reduction targets or climate pledges, it inherits sustainability initiatives from its parent company, Zentiva Group, a.s. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate-related frameworks, although specific details on these initiatives are not disclosed. As a part of the pharmaceutical industry, Solacium Pharma is positioned within a sector increasingly focused on reducing carbon footprints and enhancing sustainability practices. The absence of direct emissions data highlights the need for the company to develop and communicate its own climate strategies and performance metrics in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2024 | |
|---|---|---|
| Scope 1 | 305,480,000 | 0,000,000 |
| Scope 2 | 79,081,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 |
How Carbon Intensive is Solacium Pharma S.R.L.'s Industry?
How Carbon Intensive is Solacium Pharma S.R.L.'s Location?
Solacium Pharma S.R.L.'s Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
Solacium Pharma S.R.L.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Solacium Pharma S.R.L. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
